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Treatment of chronic kidney disease (CKD) can slow its
progression to end-stage renal disease (ESRD). However,
the therapies remain limited. Blood pressure control using
angiotensin-converting enzyme (ACE) inhibitors or
angiotensin II receptor blockers (ARBs) has the greatest
weight of evidence. Glycemic control in diabetes seems
likely to retard progression. Several metabolic disturbances
of CKD may prove to be useful therapeutic targets but
have been insufficiently tested. These include acidosis,
hyperphosphatemia, and vitamin D deficiency. Drugs aimed
at other potentially damaging systems and processes,
including endothelin, fibrosis, oxidation, and advanced
glycation end products, are at various stages of development.
In addition to the paucity of proven effective therapies, the
incomplete application of existing treatments, the education
of patients about their disease, and the transition to ESRD
care remain major practical barriers to better outcomes.
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Treatment of chronic kidney disease (CKD) aims to slow
progression to end-stage renal disease (ESRD) and to prepare
for ESRD. Because the symptoms of chronically progressive
renal failure develop slowly, therapy of CKD is usually directed
at an asymptomatic condition detected only by laboratory
testing. The task is also made more difficult as it usually
represents a late attempt at prevention. That is, the major
causes of ESRD, hypertension, and type 2 diabetes can
themselves be avoided to some degree by primary preventive
measures such as diet, weight control, and exercise. Further-
more, once hypertension or diabetes are manifest, their renal
complications can be mitigated by secondary prevention efforts
aimed at blood pressure and glycemic control. Thus, treatment
of CKD often represents an example of tertiary prevention in
populations who have failed the first lines of prevention but
who are still relatively asymptomatic. These features make
CKD therapy a formidable task in practice. However, over
the past 20 years, some effective treatments of CKD have
developed. These can delay and, in some cases, prevent ESRD.
The notion of CKD as a single entity with generic therapy
is a simplification but a useful one. Admittedly, some forms
of CKD, especially inflammatory and autoimmune ones,
require special treatments. However, even these approaches
are usually applied in addition to those used for the most
common hypertensive and diabetic causes. Viewing CKD as a
single process rests both on the effectiveness of therapy across
a range of primary diseases and on the data, suggesting that
final common physiological pathways underlie the progres-
sion of CKD irrespective of initiating insult.1–3
Cardiovascular disease (CVD) is now well known to be
common and often fatal in people with CKD.4,5 Hence,
careful attention to reducing traditional CVD risk factors in
CKD is of great importance. Nevertheless, delay of ESRD
remains a primary goal of CKD therapy simply because
specific treatments to avoid CVD in this population do not
currently exist. Standard methods of CVD prevention should
be assiduously applied in CKD. Similarly, people with CKD
should receive health maintenance applicable to the general
population such as cancer screening and vaccinations.
The definition of CKD has itself received considerable
attention. The most important consequence of the definition
is its implications for therapy of an individual patient.
Current treatment options are broadly initiated across CKD
populations because they are relatively inexpensive and safe.
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Given the low potential risk for individuals treated with these
medications, and the absence of sophisticated prognostic
tools, extended debate of CKD definitions is largely unimpor-
tant for clinical practice. If more toxic or expensive therapies
are forthcoming, or when better markers of progression
develop, then the definition may need refinement. At present,
we regard the simple definition of CKD as an estimated
glomerular filtration rate (eGFR) ofo60ml/min per 1.73m2
and/or persistent albuminuria 430mg of urinary albumin
per gram of urinary creatinine as adequate.
RENIN–ANGIOTENSIN–ALDOSTERONE SYSTEM
Angiotensin-converting enzyme (ACE) inhibitors were the
first treatment shown to be effective in slowing the
progression of diabetic nephropathy in 1993 by Lewis
et al.6 The work followed on animal studies by several
laboratories, most notably that of Barry Brenner in the
1980s.7 ACE inhibitors and angiotensin II receptor blockers
(ARBs) are standard drugs for primary hypertension.
However, they are each especially effective in slowing the
progressive decay of GFR in CKD.6,8–11 Diabetic nephropathy
has been the disease state most studied with these agents. In
both diabetes mellitus type 1 and type 2, slowing the rate of
progressive renal injury with renin–angiotensin–aldosterone
system (RAAS) inhibition has been intimately associated
with the stabilization or reduction of proteinuria.6,11 These
findings have been demonstrated in patients with micro-
albuminura and macroalbuminuria.6,12,13 In nondiabetic
renal diseases, the data for the benefits of RAAS inhibition
on progression of CKD are strongest in those patients with
proteinuria 41000mg/day according to a recent meta-
analysis.14 The AASK trial further supports this in African
Americans with hypertensive nephropathy.15 The benefit of
RAAS inhibition in subjects with nondiabetic kidney disease
without proteinuria is less clear. In certain disease states such
as autosomal dominant polycystic kidney disease, there may be
little to no benefit from ACE inhibitors and ARBs despite
measurable reductions in proteinuria.16 This is a current topic
of investigation in the HALT PKD trial.17 The exact nature of
the relationship between proteinuria and progressive renal
injury remains a topic of debate.18 It may be misleading to
interpret reductions in albuminuria as a surrogate for
improved renal function. Although some authors argue that
experimental evidence suggests that proteinuria has direct
toxic effects, currently there is no consensus that the available
evidence clearly establishes a cause and effect role.19,20 For this
reason, the significance of the antiproteinuric properties of
ACE inhibitors and ARBs is unclear.
On the contrary, there are two widely accepted mechan-
isms by which ACE inhibitors and ARBs are understood to be
beneficial agents in CKD: hemodynamic/antihypertensive
actions and anti-inflammatory/antifibrotic actions. Their
reduction of angiotensin II (AngII) levels (and subsequent
reduction in aldosterone levels) is central to both of these
pathways. In many animal models of CKD, glomerular
capillary pressures are elevated. ACE inhibitors and ARBs
reduce this capillary hypertension by both reducing arterial
perfusion pressure and relaxation of the efferent arteriole, the
dominant site of AngII action.1,7 Relief from this excessive
capillary pressure likely prevents mesangial cell proliferation
and matrix production, as well as podocyte loss.1
Subsequent to the description of beneficial hemodynamic
effects, investigators began to describe the RAAS as a
proinflammatory and profibrotic mediator. AngII activates
NF-kB (nuclear factor k-light-chain-enhancer of activated B
cells), upregulates adhesion molecules, and may directly
stimulate proliferation of lymphocytes.21,22 The net result of
these actions is a local inflammatory environment in areas
where AngII is in high concentration, namely the kidney.
AngII may also foster fibrosis via interactions with transform-
ing growth factor-b (TGF-b) and the induction of extracellular
matrix proteins such as type I procollagen, fibronectin, and
collagen type IV.23 In addition, animal models have implicated
aldosterone to be directly involved with mechanisms of
endothelial dysfunction, inflammation, and fibrosis.24 Table 1
gives a more complete list of the proposed inflammatory
mechanisms mediated by the RAAS. Using ACE inhibitors and
ARBs to quell these hostile attacks in the kidney is likely an
important factor in slowing the progression of CKD.
As ACE inhibitors and ARBs each slow progression
individually, the question has arisen as to whether the
combination would provide additional advantage. This issue
has not been definitively settled. One early report of the
COOPERATE trial claimed that the combination was super-
ior to the individual drugs.25 However, these results and their
analyses have been brought into question and retracted.26,27
These events make any conclusions drawn from the
COOPERATE trial invalid. An analysis of a study designed
to examine cardiovascular end points in subjects with
cardiovascular disease but generally good renal function
(the ONTARGET study) found lesser proteinuria with
combination ACE inhibitor and ARB therapy, but no benefit
in terms of preventing a decline in GFR.28 This study raises a
couple of interesting findings. First, the relationship between
improved proteinuria and worsening GFR contributes
further reason to question the significance of reduced
albumin excretion as a meaningful clinical outcome. Second,
the lack of improved renal end points in those receiving dual
therapy questions the validity of this treatment strategy for
slowing CKD progression. A high burden of renal vascular
atherosclerosis in the participating subjects may have
contributed to these results, and it remains unclear whether
these findings can be directly applied to broader populations
with renal dysfunction. Currently, several trials are underway
to address this, but at present there are no firm data to
support the use of combination therapy.17,29
Aldosterone contributes along with AngII to the adverse
actions of the RAAS in progressive CKD. Recognition of the
deleterious effects of aldosterone has led to attempts to
selectively block it by using the mineralocorticoid receptor
blockers.30 A large number of studies in experimental animals
have supported this approach. Several trials in human
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subjects with CKD have shown a reduction in proteinuria
when aldosterone blockade was added to an ACE inhibitor or
ARB.30–33 However, there is not yet a large enough trial to
assess the effects on decline in GFR. Moreover, hyperkalemia
is more frequent. Thus, there are no sufficient data to
recommend the addition of aldosterone blockade to standard
therapy in CKD.
Inhibition of renin is yet another means of interrupting
the RAAS. Addition of a renin inhibitor to an ARB reduced
proteinuria in diabetic nephropathy.34 The diminution of
proteinuria was with little if any further reduction in blood
pressure, and no additional side effects were noted with the
combination. A larger and longer trial is underway to test the
value of renin inhibitor addition to ACE inhibitors or ARBs
using cardiovascular and renal end points.35
In summary, blockade of the RAAS with ACE inhibitors
or ARBs has proven effective in retarding progression of
CKD. Studies are ongoing to assess the value of interrupting
the pathway simultaneously at multiple sites, but such
approaches have, at this time, not been proven more effective
than the use of ACE inhibitors or ARBs and have not been
adequately assessed for safety.
BLOOD PRESSURE
Although there is a considerable amount of overlap when
considering the beneficial effects of RAAS inhibition and
blood pressure control, it is important to appreciate them as
two separate treatment targets. The reductions in arterial and
glomerular capillary pressure affected by antihypertensive
medications dictate their beneficial effects. However, the
optimal target arterial pressure in CKD is largely a matter
of opinion. Current guidelines suggest a target of
o130/80mmHg for patients with CKD, a more stringent
control than the 140/90mmHg recommended for the general
population. A recent meta-analysis was performed to
specifically address this question.36 The study included
results from 2272 subjects with nondiabetic renal disease
involved in the MDRD, AASK, and REIN-2 trials. Overall, no
benefits in renal outcomes, cardiovascular outcomes, or
death were obtained in patients with CKD who were treated
to a goal blood pressure of 125–130/75–80mmHg as
compared with 140/90mmHg. From subgroup analysis,
proteinuria did appear to be an effect modifier. Participants
with daily proteinuria 4300mg in the AASK trial and
41000mg in the MDRD trial did show a benefit. The
ACCORD trial in type 2 diabetes compared a goal systolic
blood pressure of 140mmHg with one of 120mmHg and
found no overall benefit to the lower goal.37 Albuminuria was
less with the lower pressure but eGFR was also lower at the
end of the study in this group. However, the trial did not
target people with CKD, and on average the starting eGFRs
were 490ml/min per 1.73m2 and albumin excretion less
than the microalbumuria level. Whether a goal of 120mmHg
systolic pressure is desirable in the CKD population is
unknown but is a question to be addressed by the SPRINT
trial, which will recruit a large fraction of subjects with CKD.
Table 1 | Reported nonhemodynamic effects of renin–angiotensin–aldosterone system
Mechanism Comment Mediator
Stimulation of NF-kB A transcription factor resulting in a cascade of cytokines and other
proinflammatory factors
AngII,
AngIII, AngIV
Stimulation of ETs-1 A mediator of vascular inflammation with T-cell and macrophage/
monocyte recruitment
AngII
Adhesion molecules
Vascular cellular adhesion molecule 1
Intracellular adhesion molecule 1
Integrins
Facilitates adhesion of inflammatory cells to capillary walls AngII
Cell proliferation
Mesangial cells
Glomerular endothelial cells
Fibroblasts
Enhances structural renal damage and fibrosis AngII/Aldo
Apoptosis As opposed to cellular proliferation, under certain circumstances,
AngII instead induces apoptosis; how this is regulated is unclear
AngII
Increased TGF-b expression An important protein that results in cascading effects central to
inflammation and fibrosis
AngII/Renin
Increased connective tissue growth factor Can occur by direct stimulation by AngII or via TGF-b upregulation AngII
Increased ECM products
Type I procollagen
Fibronectin
Collagen type IV
Result in ECM accumulation and are pivotal factors that contribute
to fibrosis
AngII
Increased metalloproteinase inhibitors
Plasminogen activator inhibitor-1
Tissue inhibitor of matrix metalloproteinases
Also results in ECM accumulation due to decreased turnover AngII
Ac-SDKP hydrolysis Increases fibrosis and inflammatory cell infiltration ACE
Reactive oxygen species Leads to cellular damage Aldo
MAPK activation Contributes to mesangial injury and renal fibrosis AngII/Aldo
Abbreviations: ACE, angiotensin-converting enzyme; Ac-SDKP, N-acetyl-seryl-aspartyl-lysyl-proline; Aldo, aldosterone; Ang, angiotensin; ECM, extracellular matrix;
ETs-1, endothelins-1; MAPK, mitogen-activated protein kinase; NF-kB, nuclear factor k-light-chain-enhancer of activated B cells; TGF-b, transforming growth factor-b.
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Until we have these results, the present guideline of
130/80mmHg seems reasonable, especially for those patients
with higher amounts of proteinuria.
If first-line therapy with an ACE inhibitor or ARB fails to
achieve the target of 130/80, and often it will not, the choice
of the second agent is also largely a matter of opinion.
Addition of a diuretic has physiological appeal. In short-term
studies, the addition of a thiazide diuretic to an ARB showed
additional reduction of proteinuria in CKD, possibly
suggesting further renal protection.38 Often it is said that
thiazide diuretics lose potency in later stages of CKD
compared with loop diuretics. There is little evidence for
this contention.39 Many people with CKD will require more
than the combination of a diuretic and ACE inhibitor or
ARB to reach target blood pressures. Further choices are
similarly not based on long-term studies of progression,
but b-blockers, calcium channel blockers, and/or central
sympatholytic agents are satisfactory.
Targeting blood pressure o130/80mmHg is recom-
mended, but will often require two or more drugs.
GLYCEMIC CONTROL IN DIABETES
Glycemic control reduces the progression of renal disease as
judged by the mitigation of increasing albuminuria in both
type 1 and type 2 diabetes.40–43 For example, in the DCCT, in
type 1 diabetes, strict glycemic control compared with usual
control lessened the progression from microalbuminuria
(30–299mg albumin per g creatinine) to macroalbuminuria
(4300mg albumin per g creatinine). Similarly, in the
ACCORD trial, transitions to microalbuminuria and macro-
albuminuria were diminished by stringent glycemic control.
However, the incidence of ESRD was not different between
levels of glycemic control in ACCORD or ADVANCE, another
study of glycemic control in type 2 diabetes, and the incidence
of ESRD has been low in follow-ups to DCCT.42–44
No large-scale studies have specifically tested the
benefits of glycemic control in diabetic CKD with GFR of
o60ml/min per 1.73m2 or macroalbuminuria. Thus,
although attention to glucose control seems to afford renal
protection, this has been gauged largely by changes in
albuminuria. Evidence that glucose control can forestall
ESRD in people with established diabetic CKD is lacking. The
exact best level of glycemic control is uncertain. Because of
overall mortality risks with very stringent glycemic control,
current guidelines call for hemoglobin A1c levels of o7.0%.
At present, maintaining hemoglobin A1c of p7.0% remains
reasonable for people with established diabetic CKD.
METABOLIC DERANGEMENTS OF CKD
Acid base
Although the acidosis of CKD results from decreased renal
ammoniagenesis, ammonia production per residual GFR in
patients and per residual nephron in animals actually rises as
CKD progresses.45–48 Data in rat models of renal disease have
suggested that excess ammoniagenesis per residual nephron
causes tubulointerstitial injury because of the interaction of
ammonia with complement component, C3.49,50 Bicarbonate
supplementation reduced injury in some but not all rat
models tested.51–53
An analysis of the relation of serum bicarbonate to
progression of renal disease in a data set including over 5000
outpatients found that low serum bicarbonate level was strongly
associated with subsequent progression of kidney disease.54
Obviously, this strong association does not prove a causal
relationship, and a clinical trial is needed to determine whether
amelioration of acidosis would lessen progression. Kovesdy
et al.55 have recently reported that lower serum bicarbonate was
associated with mortality in a cohort with CKD.
Several relatively small trials of the effects of bicarbonate
supplementation on renal disease progression have been
recently reported. The first trial was randomized, but not
blinded or placebo controlled, and studied people with
advanced CKD.56 It comprised 129 subjects with estimated
creatinine clearance (CrCl) of o30ml/min who were rando-
mized to receive either sodium bicarbonate or continuation
of usual care. The treated group received an average of
14mEq/day of bicarbonate. The most striking result was a
6.5% vs. 33% incidence in ESRD over a 2-year follow-up,
treated vs. control, respectively. Another trial studied subjects
with relatively high eGFR (B75ml/min) and assigned 40
subjects each to sodium bicarbonate supplementation, sodium
chloride supplementation, or nothing.57 Sodium bicarbonate at
a dose of 0.5mEq per kg body weight per day was associated
with fewer subjects developing more advanced disease over
5 years (o60ml/min). The rate of decline in eGFR was
significantly less in those receiving sodium bicarbonate as
compared with those receiving sodium chloride or placebo.
Interestingly, urinary endothelin excretion declined with
bicarbonate treatment. In an uncontrolled trial comparing
30 patients with eGFRo60ml/min given sodium citrate for 24
months with 29 CKD patients not treated with alkali, eGFR was
higher at the end of the study in the treated group.58 An effect
of alkali on progression of kidney disease in these patients may
have been mediated by a reduction in endothelin secretion.
More recent data suggest that treatment with alkali in CKD
patients reduces both endothelin and aldosterone secretion.59
Thus, the effects of alkali supplementation on the
progression of renal disease have been tested only in small
studies with less than optimal design but with encouraging
results. Present guidelines suggest treating patients with alkali
when serum bicarbonate level decreases to o22mEq/l.
Although this is opinion based, the available human data
and the prior animal studies raise the possibility that such
treatment could retard progression.
Phosphate
Recent evidence suggests that fibroblast growth factor-23, a
phosphaturic hormone, increases early in CKD to maintain
phosphorous balance.60 Regardless of this, without inter-
vention, hyperphosphatemia regularly appears as CKD
progresses. Control of hyperphosphatemia with dietary
restriction and phosphate binders have long been mainstays
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of therapy directed at preventing bone disease. However,
animal studies more than 30 years ago also suggested that
hyperphosphatemia hastened progression to ESRD by causing
calcium–phosphate crystal deposition within the renal inter-
stitium.61 More recent observational studies have found that
elevated phosphate associates with more rapid decline in eGFR,
and also that separately it associates with CVD in CKD as well
as the general population.62–67 In parallel to this, additional
studies have also linked elevated serum fibroblast growth
factor-23 with a greater risk for progression of CKD.68,69
In recent years, the proposed pathogenetic mechanisms
for extraosseous toxicity have grown to suggest a role for
hyperphosphatemia in vascular and cardiac calcifications,
both of which are common in advanced CKD. These
calcifications may be mediated through hormonal reactions
to phosphate such as the phosphatonins and cellular
transformations of vascular smooth muscle cells to those
with more bone phenotypes.70 In any case, interventional
trials to test the efficacy of phosphate-lowering strategies for
either slowing CKD progression or preventing CVD are
lacking. Thus, phosphate control when used in CKD must be
based on data for ameliorating bone outcomes, which are
themselves modest, or at best opinion based on animal and
epidemiologic work. Further trials are needed.
Vitamin D
Deficiency of 1,25-dihydroxyvitamin D may be expected with
advancing CKD, as the kidney is the site of its synthesis.
However, low levels of its precursor 25-hydroxyvitamin D have
been linked epidemiologically to more rapid progression of
CKD.71 The physiological actions of vitamin D are multiple
and extend well beyond its classic effects on calcium,
phosphate, and bone.72 For example, vitamin D suppresses
renin secretion, and this action has been proposed as beneficial
in CKD.73 There are no long-term trials of vitamin D
supplementation in progressive renal disease using the
strongest outcomes such as reduction of GFR or incidence of
ESRD. However, in the VITAL study, a synthetic vitamin D
analog, paricalcitol, did lower albuminuria in subjects with
diabetic nephropathy.74 In this study, reduced albuminuria was
associated with a decrease in blood pressure and an increase in
eGFR, suggesting that vitamin D–mediated renin suppression
may have been the major contributing mechanism. Clearly,
clinical trials are needed to test the effect of vitamin D on hard
outcomes, and especially to test inexpensive forms such as
nutritional vitamin D, cholecalciferol.
Parathyroid hormone
Secondary hyperparathyroidism also regularly attends pro-
gressive CKD and is at least partly a consequence of
hyperphosphatemia and vitamin D deficiency. Elevated
PTH levels have also been suggested as toxic even beyond
their capacity to induce bone loss.75 However, an analysis of
published literature found that the evidence for links between
parathyroid hormone (PTH) and CVD or mortality was
poor.66 The usual recommendations for phosphate and
vitamin D should mitigate secondary hyperparathyroidism,
but whether this slows progression of CKD or lessens CVD is
uncertain. In principle, targeted suppression of PTH with a
calcimimetic would be an attractive means of testing the role
of PTH in extraosseous sequelae of CKD. However, to date,
the role of PTH in such events is untested.
Uric acid
Epidemiological studies have often found an association
between hyperuricemia and CVD.76–78 The basis for this
association is uncertain. However, over the past several years,
hypertension has been ascribed to hyperuricemia based
largely on animal studies, but human studies are few.76
One study of newly diagnosed hypertensive adolescents
found that lowering uric acid with allopurinol reduced blood
pressure.79
With regard to CKD, hyperuricemia predictably appears as
GFR declines. Furthermore, uric acid is clearly toxic to the
kidney in very high concentrations as in tumor lysis. Whether
more modest elevations of uric acid are detrimental is more
controversial. Observational studies have found modest
associations of hyperuricemia with decline in renal func-
tion.80 One small randomized but unblinded trial involved 25
patients with mixed causes of CKD. Subjects were assigned to
receive either allopurinol or conventional treatment.81 The
investigators succeeded in lowering uric acid, but in this
study blood pressure was not affected. The serum creatinine
tended to remain lower in the allopurinol-treated group, but
was not statistically different from that in the control group.
A combined end point of incident ESRD and 40% rise in
creatinine was significantly greater in the untreated group. A
second randomized control study involving 113 patients,
again with mixed causes of CKD, also showed a favorable
effect induced by allopurinol.82 In this study, those receiving
allopurinol had a mean eGFR increase of 1.3ml/min per
1.73m2 over a period of 24 months. This was a statistically
significant difference when compared with the mean eGFR
decrease of 3.3ml/min per 1.73m2 observed in the control
group. These findings occurred independent of any differ-
ences in blood pressure between the two groups. These
studies, although suggestive, are not sufficiently robust to
recommend allopurinol as a means of slowing progression.
Larger studies might be warranted except that allopurinol has
a rather high risk for allergic reactions that can be severe. If
better alternatives for uric acid–lowering drugs were available,
then larger trials would be attractive.
Anemia
Several studies have tested the efficacy and safety of therapy
of anemia with erythropoietin congeners in CKD before
dialysis.83 The largest and most persuasive study TREAT
randomized 4038 subjects with CKD due to type 2 diabetes
to a target hemoglobin of 13 g/dl, or placebo with
darbepoieten rescue if the level dropped below 9 g/dl.84 The
baseline eGFR was B35ml/min per 1.73m2 for each of
the two groups. Except for more strokes in the higher
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hemoglobin group, there were no differences in cardiovas-
cular or renal outcomes between the two groups. Approxi-
mately 16% of the subjects in each group developed ESRD
over the 4 years of study. Thus, maintaining hemoglobin
levels at 13 g/dl is unwarranted. The lower hemoglobin group
had an average level of 10.6 g/dl but received more
transfusions. The optimal level is not clear. Current guide-
lines call for levels between 10 and 12 g/dl in ESRD, and this
also seems reasonable for patients with CKD predialysis.
However, lower levels might be equally good, but in practice
a small percentage of CKD patients require treatment for
severe anemia before ESRD.
Dietary protein
Dietary protein restriction was one of the earliest therapeutic
maneuvers used in CKD. In addition to contributing to
alterations in phosphorous, metabolic acidosis, and uric acid
as described previously, other proposed mechanisms for
renal injury from increased dietary intake include altered
hemodynamics, leading to glomerular hyperfiltration, and
reduced cytokine-mediated fibrosis.85,86 Protein restriction
does seem to ameliorate some of the symptoms of advanced
CKD, and many animal studies showed that it reduced renal
injury.87 However, clinical trials have been less clear as to its
efficacy in slowing progression. A large analysis of the
available clinical trial literature concluded that low-protein
diets reduced the incidence of ESRD in nondiabetic
patients.88 Because of varying study designs, this review
could not define an optimal level of intake. Properly
constructed and monitored protein restriction can be safe.87
Probably because successful and safe protein restriction
requires much effort for physicians, dieticians, and patients,
it is not sedulously practiced. Provided that malnutrition is
avoided and the burden is acceptable to the individual
patient, a target of 0.8 g of protein per kg body weight per
day seems reasonable. However, careful monitoring of
nutritional status and attentive dietary care is needed if
protein restriction is attempted.
LIPID-LOWERING THERAPY
Abnormal lipid metabolism often accompanies renal dys-
function. Although hyperlipidemia does not in itself seem
to cause primary renal disease, it may contribute to the
progression of CKD. The hypothesis of lipid nephrotoxicity
was first generated by Moorhead et al.89 in 1982. The
proposed mechanisms parallel the injury events that lead to
atherosclerosis in other vascular beds. In the presence of
lipids, mesangial cells are stimulated to recruit macrophages
through the production of chemokines.90 Activated mesan-
gial cells and accumulated macrophages subsequently release
oxygen radical species that lead to oxidized low-density
lipoproteins. These oxidized low-density lipoproteins have
been shown to stimulate proinflammatory and profibrotic
cytokines.91 A likely integral component to this process is the
phagocytosis of lipoproteins by macrophages and mesangial
cells to produce foam cells. As evidence for this, foam cells are
frequently found in sclerotic regions of glomeruli, as well as
areas of interstitial fibrosis.92 In addition, mesangial cell
proliferation may also be directly stimulated by low-density
lipoproteins and triglyceride-rich lipoproteins.93
Experimental studies in animals and observational data in
humans support the hypothesis that lipids contribute directly
to renal injury and progression of CKD. Rats fed high-
cholesterol diets were found to have greater amounts of
glomerulosclerosis and tubulointerstitial damage compared
with those fed standard diets.94,95
In humans, a number of epidemiological studies have
suggested that elevated cholesterol and triglyceride levels
are associated with a more rapid progression of renal
dysfunction.96–98
Given this, lipid-lowering therapy to slow the progression
of CKD has generated a great deal of interest in the nephro-
logy community. Although a number of different classes of
these medications have been studied, the pertinent data
revolve around HMG-CoA (3-hydroxy-3-methyl-glutaryl-
CoA) reductase inhibitors (statins). This class of medication
seems to offer a potential benefit not just by way of
decreasing the lipoprotein burden within tissues, but also
by way of their additional anti-inflammatory affects. In
animal studies, statin therapy has been shown to reduce
macrophage recruitment into the glomerulus, limit expres-
sion of inflammatory factors including chemokines, cyto-
kines, and adhesion molecules, and decrease fibrosis and
mesangial cell expansion.99 These beneficial effects have been
seen across a number of disease models including diabetic
nephropathy, focal glomerulosclerosis, cyclosporine nephro-
toxicity, and chronic allograft dysfunction.100–103
Data in human trials supporting the benefits of statin
therapy for slowing the progression of CKD have been less
convincing. In a meta-analysis of 39,704 patients from 27
randomized, controlled, and crossover studies, treatment
with statins resulted in a small but statistically significant
favorable effect on yearly decline in eGFR (1.22ml/min/year
slower in statin recipients as compared with placebo).104 In a
subgroup analysis, those patients with cardiovascular disease
were the most likely to benefit, whereas those with diabetes or
hypertensive nephropathy or glomerulonephritis were not
found to have a statistically significant benefit. The GREACE
study evaluated the effects of a structured care algorithm for
titrating atorvastatin to reach the low-density lipoprotein
level of o100mg/dl vs. usual care in the secondary
prevention of major cardiac events. A post hoc analysis
evaluated the effects of statin therapy on change in renal
function. For those patients who received atorvastatin as part
of the structured care group the CrCl increased by 12%, and
for those who received various statins as part of the usual care
group the CrCl increased by 4.9%. In contrast, those who did
not receive any statins had a decrease in CrCl of 5.2%. These
results represent the largest benefit of any trial to date;
however, it is important to keep in mind that the study
design and the fact that this was a post hoc analysis invites
certain bias. Another meta-analysis of 15 studies including
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1384 subjects found that those treated with statins were more
likely to have reductions in albuminuria or proteinuria;
however, no hard clinical outcomes were reported.105
The recently completed Study of Heart and Renal
Protection (SHARP) is the largest randomized controlled
trial to date to study the effects of statin therapy on
progression of CKD.106 The study involved over 9438
participants, 6382 of whom had CKD and were not on
hemodialysis. Comparing those who received simvastain
20mg plus ezetimibe 10mg with those who received placebo,
there was no difference in the risk of those with CKD to
progress to ESRD. Although the study did suggest that lipid-
lowering medications are beneficial in predialysis CKD
patients to prevent major cardiovascular events, this is the
strongest evidence to date to demonstrate a lack of benefit in
slowing CKD progression with these agents. Thus, despite a
reasonably conceived hypothesis, and supporting experimen-
tal evidence in animal studies, current human data do not
convincingly show a significant benefit from statins for
altering the disease course of CKD.
SELECTED NEW THERAPIES
Pirfenidone
Pirfenidone is a synthetic molecule with antifibrotic proper-
ties that has emerged as a promising oral treatment for CKD.
Although the exact mechanism of action is unknown, the
effects of pirfenidone seem to be mediated through
interruptions in the TGF-b pathway.107 Mesangial cell
cultures treated with pirfenidone have shown a reduction
of TGF-b production, antagonism of TGF-b signaling,
inhibition of TGF-b-induced reactive oxygen species genera-
tion, and a reduction of TGF-b-mediated matrix production.
In a murine model of diabetic nephropathy, pirfenidone
significantly reduced mesangial matrix expansion indepen-
dent of alterations in albuminuria or blood glucose levels.107
Similar findings have been found in rat models of post-
adaptive focal segmental glomerulosclerosis.108
Clinical trials have shown encouraging results for the use
of pirfenidone in the treatment of various nonrenal
fibrotic diseases including cirrhosis, multiple sclerosis, and
pulmonary fibrosis.109–111 Specific to kidney disease, an
open-label, observational study of 18 subjects with focal
segmental glomerulosclerosis and a mean baseline GFR of
26ml/min per 1.73m2 compared the change in GFR during
a 12-month baseline period with a subsequent 12-month
treatment period with pirfenidone.112 Although the GFR
declined throughout both periods in all patients, the
median monthly GFR decline rate was significantly less
during the treatment period as compared with the baseline
period (0.45 vs. 0.61ml/min per 1.73m2; Po0.01). A
phase II randomized controlled trial involving 77 partici-
pants with diabetic nephropathy (eGFR 20 to 75ml/min per
1.73m2) was recently completed.113 The subjects receiving a
1200mg dose of pirfenidone not only had a significant
benefit with regard to change in eGFR as compared with
placebo, but also actually had a mean increase in eGFR of
3.8ml/min per 1.73m2 over 54 weeks. A 2400mg dose
group was also included; however, a significant dropout rate
occurred in these subjects and no significant change in
eGFR as compared with placebo was found. Interestingly,
inflammatory biomarker levels were highly correlated with
baseline eGFR in this study. No significant changes in
biomarker levels occurred as a result of treatment with
pirfenidone. Overall, these results are promising, and it will
be interesting to see whether larger studies continue to show
a benefit for using this medication to treat diabetic
nephropathy.
Bardoxolone methyl
Bardoxolone methyl is the first member of a new antioxidant
inflammation modulator drug class. Bardoxolone methyl and
other antioxidant inflammation modulators activate nuclear
factor-erythroid 2-related factor 2, a transcription factor that
controls over 250 cytoprotective proteins.114 The net result is
an inhibition of immune-mediated inflammation at the
tissue level, which may protect against end-organ damage.
Results from a recently completed phase IIb clinical trial
reported that bardoxolone methyl has a positive effect on the
progression of diabetic nephropathy.115 In this multicenter,
randomized, controlled trial sponsored by the manufacturer
of the drug, 227 adults with diabetes mellitus type 2 and
moderate-to-severe CKD (eGFR 20–45ml/min per 1.73m2)
were randomized to receive either bardoxolone methyl or
placebo. Almost all of the patients were receiving either an
ACE inhibitor or an ARB and had well-controlled serum
glucose and blood pressure levels. Over the course of 24
weeks, patients receiving 25, 75, or 150mg of bardoxolone
methyl all had statistically significant increases in mean eGFR
as compared with those receiving placebo (between-group
differences in eGFR were 8.2, 11.4, and 10.4ml/min per
1.73m2, respectively). Continued follow-up found that these
benefits persisted over 52 weeks. Surprisingly, improvements
in GFR were seen as early as 4 weeks, and this suggests some
skepticism about whether the improved GFR was truly a
result of reduced inflammation and sustainable changes in
kidney structure or was a more temporary change resulting in
improved GFR due to altered hemodynamics. Also raising
concern was the increase in frequency of adverse events such
as muscle spasms, nausea, hypomagnesemia, and decreased
appetite seen in those receiving bardoxolone methyl. The
suggestion that this drug may actually improve GFR in
patients with diabetic nephropathy is intriguing; however,
more long-term studies with larger groups are needed to
validate its effects.
Endothelin-1 antagonism
Endothelins are a group of related peptides with powerful
vasoconstrictor properties. Endothelin-1 (ET-1) is the
predominant isoform in the human kidney and acts on a
wide distribution of receptors throughout the renal vascu-
lature and collecting system.116 ET-1 contributes to renal
dysfunction through multiple mechanisms including arterial
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vasoconstriction, glomerular hypertension, increased protei-
nuria, and interstitial fibrosis.
ET-1 blockade has been studied as a potential treatment
strategy for CKD. Animal studies have demonstrated
elevations of ET-1 after subtotal nephrectomy.117 Treatment
with ET-1 antagonist in these models has shown not only
reductions in proteinuria, but also improvements in
CrCl.117,118 These promising findings provided proof of
concept and have led to human trials. In one study,
antagonism of the endothelin type A receptor (ETa)
improved renal blood flow and reduced renal vascular
resistance in subjects with CKD.119 However, results from a
large, multicenter, randomized, controlled trial have raised
serious questions about the safety of these agents. The study
compared the efficacy of avosentan with placebo for
treatment of CKD progression in subjects with diabetic
nephropathy.120 After a median follow-up of only 4 months,
the trial was prematurely terminated owing to an excess of
cardiovascular events in the avosentan-treated group. It is
noteworthy that those in the treatment group did have
significantly less proteinuria, but there was no difference in
the primary composite end point of time to doubling of
serum creatinine, ESRD, or death. A more recent trial tested
another ETa antagonist, atrasentan, in 89 subjects with
diabetic nephropathy.121 Reported to be more selective for
the ETa receptor than the ETb receptor as compared with the
previously mentioned avosentan, it was felt that atrasentan
would result in fewer safety concerns. In this study, all
patients were already receiving a RAAS blocking agent. No
difference in albumin excretion was found with a 0.25mg
dose group; however, 0.75 and 1.75mg dose groups did result
in a significant reduction. The most common side effect was
peripheral edema, and this was only significantly more
frequent in the 1.75mg dose group. This study provides some
suggestion that both ETa receptor selectivity and dose may be
important with regard to the safety profile of these
medications. Whether reductions in albumin excretion will
translate into improvements in more robust renal outcomes
is unclear. Until additional studies address this, and more
evidence becomes available to clearly support the safety of
endothelin antagonists, it remains questionable whether these
agents will become a viable treatment option for CKD.
INHIBITORS OF ADVANCED GLYCATION END PRODUCTS
Advanced glycation end products (AGEs) form from the
nonenzymatic glycation of proteins by glucose and its
metabolites. AGEs facilitate cellular damage by directly
modifying cellular proteins and altering their function or
by binding to specific AGE receptors that induce a broad
range of cellular responses leading to injury. While implicated
as a major pathogenic mechanism in diabetic nephropathy,
AGEs also contribute to kidney injury in other forms of
nondiabetic renal disease and aging.122 The use of direct
therapeutics that disrupt the AGE/AGE receptor axis is a
developing treatment strategy.123 In addition to common
therapies such as RAAS inhibitors, statins, aspirin, and
metformin, more specific agents for inhibition of AGE
formation or AGE receptor blockade have been developed
and studied. A number of these agents have shown potential
to treat CKD in animal studies.124–129 Aminoguanidine was
the first AGE inhibitor to be studied in humans. Although
proteinuria was decreased in type 1 diabetics during a phase
III trial, no significant improvement on the progression to
overt nephropathy was found.130 This study was terminated
early because of safety concerns and apparent lack of efficacy.
Pyridoxamine is a vitamin B6 derivative. Phase II studies in
subjects with diabetes mellitus type 1 and type 2 demon-
strated it to be well tolerated and showed a statistically
significant slower decrease in creatinine over 24 weeks.131
Other agents in this class have been used in human studies as
well; however, their specific benefit on renal outcomes has
not yet been evaluated.132,133 These medications have not yet
proven clear efficacy for treatment of CKD, but given the
promising experimental data, there are likely to be more
clinical trials to come in the near future.
DELIVERY OF CKD CARE
Patients with CKD have many challenges including manage-
ment of multiple medications, major changes in diet, and
surgery for dialysis access months before any symptoms of
kidney failure occur. Multidisciplinary CKD programs use
patient education, nutrition resources, and guideline-driven
nephrology care to achieve the goals of decreasing cardio-
vascular morbidity, slowing the progression of renal disease,
and improving the transition to dialysis or transplant. These
programs are heterogeneous between different practices but
often include a subset of nephrologists, physician assistants
or nurse practitioners, nurses, social workers, dieticians, and
pharmacists. Many of the services that are included in these
programs such as social workers, nutrition counseling,
nursing care, and pharmacist interventions are not paid for
by standard fee-for-service payments; therefore, there is a
large need to prove that these interventions are clinically
effective as well as cost effective. There is growing literature
that shows that multidisciplinary programs can decrease
hospitalizations, improve arterial–venous access placement
before hemodialysis, and decrease mortality both before and
after the initiation of dialysis.
Using evidence-based guidelines has been shown to
improve outcomes of patients with CKD. One study by
Snyder and Collins134 demonstrated that adherence to the
Kidney Disease Outcomes Quality Initiative preventive
health-care guidelines decreased atherosclerotic heart disease.
These authors found that the more preventive measures used
per year, including two creatinine measurements, lipid
measurement, calcium–phosphorus measurement, PTH mea-
surement, HbA1c measurement, and influenza vaccine,
decreased the risk of atherosclerotic heart disease in a high-
risk Medicare cohort with CKD. Guideline-driven care in a
multidisciplinary program is often implemented by a
physician extender. Lee et al.135 showed that a nurse
practitioner using guideline-directed care was more effective
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in decreasing hospitalizations after initiation of dialysis. They
also had a substantial increase in patients starting dialysis
with an arterial–venous access in 5 years; 62% had
arterial–venous access in the nurse practitioner group
compared with 20% in a renal hypertension clinic.135
Several other studies also showed decreased hospitaliza-
tion rates and improved arterial–venous access using a
multidisciplinary model. Cohorts of patients who had
attended multidisciplinary programs in California, Canada,
and Taiwan showed dialysis starts with increased number of
functioning arterial–venous accesses, and with either de-
creased number of inpatient days or decreased number of
hospitalizations.136–138 Decreased hospitalizations by out-
patient dialysis starts and the use of arterial–venous access
achieved by multidisciplinary programs also result in health-
care savings. According to the USRDS (United States Renal
Data System) database, the inpatient cost per member per
month for dialysis initiation ranges from $9846 for Medicare
recipients up to $22,841 for patients with commercial
insurance; this could be greatly reduced by increasing
outpatient dialysis starts.139 A functional arterial–venous
fistula is associated with a difference of approximately $3000
dollars per patient per year compared with a hemocatheter,
and the total yearly dialysis expenditure for a patient with a
hemocatheter averages $90,110 compared with $64,701 for a
patient with a fistula.139 Proponents of multidisciplinary
programs maintain that the cost savings of these programs
outweigh the personnel and increased health-care utilization
costs. A study in Taiwan found that the patients in the
interdisciplinary program studied for 6 months before
dialysis initiation had a mean cost of $1200 per patient less
than those patients who had seen a nephrologist only.138
Patient education and multidisciplinary care through
different models have decreased both the rate of kidney
disease progression and the rate of reaching ESRD. A
randomized controlled trial demonstrated that one 90-min
educational session with a follow-up phone call every 3 weeks
significantly decreased the time to dialysis by B3 months in
patients expected to start dialysis within 6–18 months.140
Richards et al.141 studied a cohort of patients with eGFRs
o30ml/min in a primary care program in England who had
access to a nurse, patient education, medication manage-
ment, and dietary advice. They found that the program
significantly decreased the rate of fall of eGFR, and the
impact was greatest in those patients whose eGFR was falling
the fastest,45ml/min in the 9 months before the study. The
positive impact of multidisciplinary programs has also been
demonstrated in patients with higher eGFRs, those between
30 and 59ml/min. A study in a health maintenance
organization population found that the rate of eGFR decline
was less in patients who enrolled in an interdisciplinary care
model compared with historical controls.142 Given that the
average cost per patient per year for hemodialysis, peritoneal
dialysis, and transplant is $77,506, $57,639, and $26,668,
respectively, delaying ESRD would likely result in a
considerable cost savings.139
Access to a nephrologist for 41 year before dialysis
initiation has been shown to decrease mortality for patients
with CKD.143,144 Multidisciplinary care has also been shown
to decrease mortality both before and after the initiation of
dialysis. Two studies compared outcomes of patients who
initiated hemodialysis and found that those patients who had
been followed up in a multidisciplinary program before
dialysis starts had lower mortality rates.145,146 Hemmelgarn
et al.147 compared a predialysis cohort of patients who had
multidisciplinary care to a cohort of propensity-matched
controls and found significantly decreased mortality rates in
the patients exposed to the multidisciplinary intervention.
Multidisciplinary care has been shown to improve
outcomes in patients with CKD and is likely cost effective.
However, most of the evidence is from small cohorts and not
randomized controlled trials. In addition, there is likely a
publication bias with only centers that have positive
outcomes publishing their data. These programs likely
improve care in this patient population, and more rigorous
study is needed to demonstrate their benefit and ability to
decrease costs.
CONCLUSIONS
The increasing use of treatments to attenuate progressive
CKD, most notably glycemic control in diabetic CKD and
blood pressure treatment with ACE inhibitors and ARBs in
almost all forms of CKD, have coincided with a plateau in the
incidence of ESRD in the United States over the past few
years.139 This is a very welcome change after decades of
increasing incidence and is likely related to the use of these
treatment options. However, a stable rate of incidence at over
100,000 people per year is not good enough, and the field has
not seen a truly new therapy for slowing progression in over a
decade.
Organized multidisciplinary clinics seem to be an effective
means to apply the tools we have. However, these tools are far
from perfect. One can consider a clinical trial as something
akin to such a clinic, and subjects in the trials taking ACE
inhibitors or ARBs still progressed, although more slowly
than subjects on the comparators. If a better result than a
stable incidence of ESRD is to be achieved, then new
therapies are needed. Obviously, basic research will be
critical. Although beyond the scope of this review, recent
findings such as the deleterious reactivation of the role of
NOTCH pathway in CKD and the discovery of APOL 1
(apolipoprotein L, 1) polymorphisms conferring risk for focal
segmental sclerosis are strong examples of such basic research
with potential drug targets.148,149 New reliable markers of
renal disease that would allow faster, smaller, and therefore
less expensive trials are highly desirable. Finally, testing of
relatively simple and cheap approaches such as bicarbonate
and nutritional vitamin D that will not be supported by the
pharmaceutical industry seems overdue.
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